TheraCryf PLC

TCF

Company Profile

  • Business description

    TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.

  • Contact

    Congleton Road
    Alderley Park
    Nether AlderleyCheshireSK10 4TG
    GBR

    T: +44 1625315090

    E: [email protected]

    https://www.evgen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

    9

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,175.1049.900.61%
CAC 407,536.2633.480.45%
DAX 4022,242.45177.940.81%
Dow JONES (US)40,113.5020.100.05%
FTSE 1008,415.257.810.09%
HKSE21,980.7470.980.32%
NASDAQ17,382.94216.901.26%
Nikkei 22535,705.74666.591.90%
NZX 50 Index12,017.8461.370.51%
S&P 5005,525.2140.440.74%
S&P/ASX 2007,968.2047.700.60%
SSE Composite Index3,295.062.23-0.07%

Market Movers